Упрощенная HTML-версия
138
Psychoneuroendocrinology. - 1997. - N 7. - P. 549-558.
217. Kosano, Н., Nishigiri, Н. Synthetic estrogens-new farmacologice actions and
mechanism // Nippon rinsho. - 1994. - N 52. - 3. - P. 586-592.
218. Кotelovitz, М., Kitchens, С., Ware, М. е. а. Combination estrogen and progestogen
replacement therapy does not adversely affect coagulation // Obstetr. Gynecol. -
1983. - N 62. - 5. - P. 596-600.
219. Kronenber, F., Trenkwalder, Е., Sturm, W. e.а. LDL-unbound apolipo-protein (а)
and carotid atherosclerosis in hemodialisis patients // Clin. Genet. - 1997. - N 52. -
5. - P. 377-386.
220. Kuhl, Н.Effect оf progesterons on haemostasis // Maturitas. - 1996. - N 24. - 1. - Р.
1-19.
221. Kuhl, Н. Hormonal contraception and substitution therapy: the importance of pro-
gestogen for cardiovascular diseas // Geburtshilfe Frauenheilrund. - 1992. - N 52. -
121. - P. 653-662.
222. Lachnit-Fixon, U. The role of triphasic levonorgestrel in oral contraception а re-
view of metabolic and hemostatic effects // Gynecol. Endocrinol. - 1996. - N 10. -
3. - Р. 207-218.
223. Lentz, S.R. Effect of hyperhomocysteinemia on protein C activation and activity //
Blood. - 2010. - N 100. - 6. - P. 2108-2112.
224. Lidegaard, Q. et al. Hormonal contraception and risk venous thromboembolism:
national follow-up study // BMJ. - 2009. - N 339. - P. 2890.
225. Lindberg, U.В., Crona, N., Stigendal, L. е.а. А comparison between effect of es-
tradiol valerate and low dose ethinyl estradiol on haemostasis parameters //
Thromb. Haemost. - 1989. - N 61. -1. - P. 65-69.
226. Lip, G.Y., Blann, А.D. Von Willebrand factor and its relevance to cardiovascular
disorders // Br. Heart. J. - 1995. - N 74. - 6. - P. 580-583.
227. Lip, G.Y., Blann, А.D., е.а. Effect of hormone-replacement on hemostatic factor,
lipid factors, and epithelial function in women undergoing surgical menopause //
Am. Heart J. - 1997. - N 134. - 4. - P. 764-771.
228. Livio, М., Mannucci, P.М., Vigano, G. е.а. Conjugated estrogens for the manage-